These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 20051382)

  • 21. The GPR 55 agonist, L-α-lysophosphatidylinositol, mediates ovarian carcinoma cell-induced angiogenesis.
    Hofmann NA; Yang J; Trauger SA; Nakayama H; Huang L; Strunk D; Moses MA; Klagsbrun M; Bischoff J; Graier WF
    Br J Pharmacol; 2015 Aug; 172(16):4107-18. PubMed ID: 25989290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55.
    Yamashita A; Oka S; Tanikawa T; Hayashi Y; Nemoto-Sasaki Y; Sugiura T
    Prostaglandins Other Lipid Mediat; 2013 Dec; 107():103-16. PubMed ID: 23714700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lysophosphatidylinositol causes neurite retraction via GPR55, G13 and RhoA in PC12 cells.
    Obara Y; Ueno S; Yanagihata Y; Nakahata N
    PLoS One; 2011; 6(8):e24284. PubMed ID: 21904624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What is the natural ligand of GPR55?
    Okuno T; Yokomizo T
    J Biochem; 2011 May; 149(5):495-7. PubMed ID: 21324983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of l-α-lysophosphatidylinositol/GPR55 MAP kinase signalling by CB2 receptor agonists: identifying novel GPR55 inhibitors.
    Anavi-Goffer S; Irving AJ; Ross RA
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):303-10. PubMed ID: 27089417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo.
    Whyte LS; Ryberg E; Sims NA; Ridge SA; Mackie K; Greasley PJ; Ross RA; Rogers MJ
    Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16511-6. PubMed ID: 19805329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca(2+) release in rat mesenteric artery endothelial cells.
    AlSuleimani YM; Hiley CR
    Br J Pharmacol; 2015 Jun; 172(12):3043-57. PubMed ID: 25652040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors.
    Zhao P; Abood ME
    Life Sci; 2013 Mar; 92(8-9):453-7. PubMed ID: 22820167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of GPR55 in rat white adipose tissue and serum LPI by nutritional status, gestation, gender and pituitary factors.
    Imbernon M; Whyte L; Diaz-Arteaga A; Russell WR; Moreno NR; Vazquez MJ; Gonzalez CR; Díaz-Ruiz A; Lopez M; Malagón MM; Ross RA; Dieguez C; Nogueiras R
    Mol Cell Endocrinol; 2014 Mar; 383(1-2):159-69. PubMed ID: 24378736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GPR55-mediated effects on brain microvascular endothelial cells and the blood-brain barrier.
    Leo LM; Familusi B; Hoang M; Smith R; Lindenau K; Sporici KT; Brailoiu E; Abood ME; Brailoiu GC
    Neuroscience; 2019 Aug; 414():88-98. PubMed ID: 31279825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The L-α-Lysophosphatidylinositol/G Protein-Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis.
    Fondevila MF; Fernandez U; Gonzalez-Rellan MJ; Da Silva Lima N; Buque X; Gonzalez-Rodriguez A; Alonso C; Iruarrizaga-Lejarreta M; Delgado TC; Varela-Rey M; Senra A; Garcia-Outeiral V; Novoa E; Iglesias C; Porteiro B; Beiroa D; Folgueira C; Tojo M; Torres JL; Hernández-Cosido L; Blanco Ó; Arab JP; Barrera F; Guallar D; Fidalgo M; López M; Dieguez C; Marcos M; Martinez-Chantar ML; Arrese M; Garcia-Monzon C; Mato JM; Aspichueta P; Nogueiras R
    Hepatology; 2021 Feb; 73(2):606-624. PubMed ID: 32329085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GPR55 ligands promote receptor coupling to multiple signalling pathways.
    Henstridge CM; Balenga NA; Schröder R; Kargl JK; Platzer W; Martini L; Arthur S; Penman J; Whistler JL; Kostenis E; Waldhoer M; Irving AJ
    Br J Pharmacol; 2010 Jun; 160(3):604-14. PubMed ID: 20136841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A putative lysophosphatidylinositol receptor GPR55 modulates hippocampal synaptic plasticity.
    Hurst K; Badgley C; Ellsworth T; Bell S; Friend L; Prince B; Welch J; Cowan Z; Williamson R; Lyon C; Anderson B; Poole B; Christensen M; McNeil M; Call J; Edwards JG
    Hippocampus; 2017 Sep; 27(9):985-998. PubMed ID: 28653801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation.
    Piñeiro R; Maffucci T; Falasca M
    Oncogene; 2011 Jan; 30(2):142-52. PubMed ID: 20838378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells.
    Bondarenko A; Waldeck-Weiermair M; Naghdi S; Poteser M; Malli R; Graier WF
    Br J Pharmacol; 2010 Sep; 161(2):308-20. PubMed ID: 20735417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptide targeting of lysophosphatidylinositol-sensing GPR55 for osteoclastogenesis tuning.
    Mosca MG; Mangini M; Cioffi S; Barba P; Mariggiò S
    Cell Commun Signal; 2021 Apr; 19(1):48. PubMed ID: 33902596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lysophosphatidylinositol Promotes Chemotaxis and Cytokine Synthesis in Mast Cells with Differential Participation of GPR55 and CB2 Receptors.
    Martínez-Aguilar LM; Ibarra-Sánchez A; Guerrero-Morán DJ; Macías-Silva M; Muñoz-Bello JO; Padilla A; Lizano M; González-Espinosa C
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells.
    Ford LA; Roelofs AJ; Anavi-Goffer S; Mowat L; Simpson DG; Irving AJ; Rogers MJ; Rajnicek AM; Ross RA
    Br J Pharmacol; 2010 Jun; 160(3):762-71. PubMed ID: 20590578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist.
    Brown AJ; Daniels DA; Kassim M; Brown S; Haslam CP; Terrell VR; Brown J; Nichols PL; Staton PC; Wise A; Dowell SJ
    J Pharmacol Exp Ther; 2011 Apr; 337(1):236-46. PubMed ID: 21233197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GPR55-dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans.
    Liu B; Song S; Ruz-Maldonado I; Pingitore A; Huang GC; Baker D; Jones PM; Persaud SJ
    Diabetes Obes Metab; 2016 Dec; 18(12):1263-1273. PubMed ID: 27561953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.